浙江医药
(600216)
| 流通市值：91.64亿 | | | 总市值：91.96亿 |
| 流通股本：9.62亿 | | | 总股本：9.65亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,249,164,467.2 | 7,794,145,971.37 | 5,876,518,447.27 | 3,937,942,897.55 |
| 营业收入 | 2,249,164,467.2 | 7,794,145,971.37 | 5,876,518,447.27 | 3,937,942,897.55 |
| 二、营业总成本 | 2,131,384,649.46 | 7,681,665,559.36 | 5,607,285,954.16 | 3,702,739,461.73 |
| 营业成本 | 1,508,814,448.88 | 5,269,878,689.98 | 3,903,509,995.66 | 2,605,226,938.66 |
| 税金及附加 | 20,531,870.82 | 78,428,557.7 | 53,539,115.05 | 33,566,826.88 |
| 销售费用 | 288,699,872.16 | 1,045,588,220.72 | 755,074,640.99 | 468,865,070.02 |
| 管理费用 | 115,116,312.58 | 445,186,095.66 | 308,718,579.07 | 198,449,307.21 |
| 研发费用 | 196,215,236.98 | 860,072,434.06 | 607,134,841.28 | 430,102,351.06 |
| 财务费用 | 2,006,908.04 | -17,488,438.76 | -20,691,217.89 | -33,471,032.1 |
| 其中:利息费用 | 6,800,707.12 | 28,384,141.56 | 21,282,957.96 | 14,409,347.12 |
| 其中:利息收入 | 4,788,911.88 | 16,512,032.57 | 12,584,586.89 | 8,130,371.02 |
| 加:公允价值变动收益 | -6,963,214.95 | -10,099,353.1 | -4,714,569.07 | 5,315,635.26 |
| 加:投资收益 | -1,500,647.53 | -3,504,843.76 | -603,058.29 | 2,705,548.93 |
| 资产处置收益 | -849,636.57 | 330,155,867.41 | -752,178.79 | -62,488.31 |
| 资产减值损失(新) | -26,259,889.15 | -137,208,398.87 | -64,500,663.9 | -34,422,727.59 |
| 信用减值损失(新) | -1,887,221.37 | 28,214,492.4 | 17,385,441.58 | 22,751,501.94 |
| 其他收益 | 21,478,602.1 | 60,120,089.01 | 43,206,763.33 | 21,325,743.3 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 101,797,810.27 | 380,158,265.1 | 259,254,227.97 | 252,816,649.35 |
| 加:营业外收入 | 282,569.5 | 1,795,020.58 | 24,464,480.65 | 24,326,258.06 |
| 减:营业外支出 | 1,035,915.32 | 18,674,578.73 | 15,336,121.69 | 14,227,809.23 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 101,044,464.45 | 363,278,706.95 | 268,382,586.93 | 262,915,098.18 |
| 减:所得税费用 | 21,681,136.59 | 86,484,579.11 | 87,516,878.61 | 75,914,587.62 |
| 六、净利润 | 79,363,327.86 | 276,794,127.84 | 180,865,708.32 | 187,000,510.56 |
| 持续经营净利润 | 79,363,327.86 | 276,794,127.84 | 180,865,708.32 | 187,000,510.56 |
| 归属于母公司股东的净利润 | 109,649,638.31 | 429,639,626.26 | 301,338,595.24 | 272,261,125.88 |
| 少数股东损益 | -30,286,310.45 | -152,845,498.42 | -120,472,886.92 | -85,260,615.32 |
| (一)基本每股收益 | 0.11 | 0.45 | 0.31 | 0.28 |
| (二)稀释每股收益 | 0.11 | 0.45 | 0.31 | 0.28 |
| 八、其他综合收益 | -3,950,569.56 | 11,713,075.31 | 5,759,087.09 | 13,968,045.4 |
| 归属于母公司股东的其他综合收益 | -3,706,960.26 | 11,043,585.59 | 5,482,416.32 | 13,260,059.25 |
| 九、综合收益总额 | 75,412,758.3 | 288,507,203.15 | 186,624,795.41 | 200,968,555.96 |
| 归属于母公司股东的综合收益总额 | 105,942,678.05 | 440,683,211.85 | 306,821,011.56 | 285,521,185.13 |
| 归属于少数股东的综合收益总额 | -30,529,919.75 | -152,176,008.7 | -120,196,216.15 | -84,552,629.17 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-26 | 2023-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |